Press

2018-02-20

YEAR END REPORT KANCERA  AB (publ) 1st January – 31st December 2017

PERIOD 1 JAN – 31 DEC 2017 IN BRIEF • Net turnover for the period amounted to SEK 0.1 million (0.3 million). For the fourth quarter, turnover amounted to 0.0 MEK (0.1 M). • R & D expenses for the period amounted to...

Read More
2017-11-21

Kancera performs the second partial payment for the Fractalkine project

According to the agreement with Acturum Real Estate AB, the second partial payment for the Fractalkine project is due when the drug candidate KAND567 has been given to a certain number of subjects in the ongoing Phase Ia study.Therefore,...

Read More
2017-11-17

INTERIM REPORT FOR KANCERA  AB (publ) 1st January – 30th September 2017

PERIOD 1 JAN – 30 SEPT 2017 IN BRIEF • R&D expenses for the period amounted to SEK 39.8 million (13.3 million ), of which the third quarter amounted to SEK 14.7 million (4.6 million ) • Operating profit for the period amounted to...

Read More
2017-02-21

INTERIM REPORT FOR KANCERA AB (PUBL) Q4 2016. January 1st – December  31st 2016

THE PERIOD JANUARY – DECEMBER 2016 IN BRIEF R&D expenses for the period amounted to SEK 19,1M (SEK 20,4M) of which the fourth quarter constituted SEK 5.8M (SEK 8,3M). Operating income for the period amounted to SEK -22,3M (SEK -19.7M)...

Read More
2016-11-18

Interim Report for Kancera AB (publ) Q3 2016, January 1 – September 30, 2016

The period January to September 2016 in brief  R&D expenses for the period amounted to SEK 13.3m (SEK 12.1m) of which the third quarter constituted SEK 4.6m (SEK 3.2m).  Operating income for the period amounted to SEK -15.8m (SEK...

Read More
2016-08-19

Interim Report for Kancera AB (publ) Q2 2016 January 1 – June 30, 2016

As a consequence of the acquisition of the subsidiary Kancera Förvaltning AB on 2016-06-16, the present Interim Report, Q2 2016, is prepared in accordance with IAS 34 and related parts of the Annual Accounts Act. The consolidated financial statements...

Read More
2016-05-03

Interim Report for Kancera AB (publ) Q1 2016, January 1 – March 31, 2016

The period January to March 2016 in brief R&D expenses for the period amounted to SEK 4.2m (SEK 4.2m). Operating income for the period amounted to SEK -5.1m (SEK 4.9m). Income after financial items for the period amounted to...

Read More
2016-02-19

Interim Report for Kancera AB (publ) Q4 2015, January 1 – December 31, 2015

The period January to December 2015 and the fourth quarter 2015 in brief R&D expenses for the period amounted to SEK 20.4m (SEK 13.7m) of which the fourth quarter constituted SEK 8.3m (SEK 4.1m). Following EU’s approval of Kancera’s...

Read More
2015-11-20

Interim Report for Kancera AB (publ) Q3 2015. January 1 – September 30, 2015.

The period January to September 2015 and the third quarter 2015 in brief R&D expenses for the period amounted to SEK 12.1m (SEK 9.6m) of which the third quarter constituted SEK 3.2m (SEK 2.7m). Operating income for the period...

Read More
2015-08-21

Interim Report for Kancera AB (publ) Q2 2015, January 1 – June 30, 2015

The period January to June 2014 and the second quarter 2015 in brief R&D expenses for the period amounted to SEK 8.8m (SEK 6.9m) of which the second quarter constituted SEK 4.6m (SEK 3.4m). Operating income for the period...

Read More